(3R,3aR,6R,6aR)-6-[[6-chloro-5-(4-piperidin-1-ylphenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3R,3aR,6R,6aR)-6-[[6-chloro-5-(4-piperidin-1-ylphenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol
• 化学式: C₂₄H₂₆ClN₃O₄
• 分子量: 455.941
• InChiKey: FXDKTXIGLSFDBJ-FAYOUJPWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  79.8
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS<br/>[FR] NOUVEAUX DÉRIVÉS D'INDOLE UTILES EN TANT QU'AGENTS ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014139388A1

  公开（公告）日：2014-09-18

  Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，可能在治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病中有用。本发明的化合物可能在治疗2型糖尿病、高血糖、代谢综合征、肥胖、高胆固醇血症和高血压方面有用。
• NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS
  申请人：ACTON, III John J.

  公开号：US20160002224A1

  公开（公告）日：2016-01-07

  Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，并可用于治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病。本发明的化合物可用于治疗2型糖尿病、高血糖、代谢综合征、肥胖症、高胆固醇血症和高血压。
• AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：US20170273955A1

  公开（公告）日：2017-09-28

  Disclosed is a compound which is useful as an AMPK activator. A compound represented by formula: or its pharmaceutically acceptable salt, wherein X is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocyclyl; R 1 is hydrogen, halogen, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted acyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, or substituted or unsubstituted alkyloxycarbonyl; R 2 is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, or the like; R 3 is halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, or the like; and R 4 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or the like.
• US9650375B2
  申请人：——

  公开号：US9650375B2

  公开（公告）日：2017-05-16
• US9980948B2
  申请人：——

  公开号：US9980948B2

  公开（公告）日：2018-05-29